It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Studies about thymic B cells are scarce in the literature, but it was suggested that they can exert modulatory and regulatory functions on the immune system. Thymic B cells can play some role in regulating the most frequent allergic background worldwide, the atopy induced by the mite Dermatophagoides pteronyssinus (Der p). Here, we aimed to evaluate if the polyclonal IgG repertoire produced by Der p-atopic individuals can influence the homing and cytokine profile of human thymic B derived from non-atopic children aged less than seven days. With this purpose, we produced polyclonal IgG formulations and cultivated human thymocytes in their presence. We also assessed IgG subclasses and the direct interaction of IgG with thymic B cell membranes. Our results could demonstrate that Der p-atopic IgG could not reduce the expression of α4β7 homing molecule as observed in response to the other IgG formulations and could reduce the frequency of IFN-γ- and IL-9-producing thymic B cells compared to the mock condition. Der p-atopic IgG could also induce thymic IL-10-producing B cells compared to control conditions. The IgG derived from Der p-atopic individuals failed to diminish the population of IL-13-producing thymic B cells, unlike the reduction observed with other IgG formulations when compared to the mock condition. All IgG formulations had similar levels of IgG subclasses and directly interacted with thymic B cell membranes. Finally, we performed experiments using peripheral non-atopic B cells where IgG effects were not observed. In conclusion, our observation demonstrates that IgG induced in allergic individuals can modulate non-atopic thymic B cells, potentially generating thymic B cells prone to allergy development, which seems to not occur in mature B cells.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Santo Amaro University (UNISA), Post Graduation Program in Health Sciences, São Paulo, Brazil (GRID:grid.412283.e) (ISNI:0000 0001 0106 6835)
2 University of Sao Paulo, Laboratory of Medical Investigation LIM-56, Division of Clinical Dermatology, Medical School, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
3 Santo Amaro University (UNISA), Post Graduation Program in Health Sciences, São Paulo, Brazil (GRID:grid.412283.e) (ISNI:0000 0001 0106 6835); University of Sao Paulo, Laboratory of Medical Investigation LIM-56, Division of Clinical Dermatology, Medical School, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
4 Brigham and Women’s Hospital, Harvard Medical School, Ann Romney Center for Neurologic Diseases, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X)